Could Eli Lilly Successfully Treat Heart Failure With Its Diabetes Drug?
Eli Lilly (NYSE: LLY) made more than $1.1 billion last year from Jardiance in treating type 2 diabetes. The company could be on its way to making even more money with the drug after reporting successful results from a late-stage study for heart failure. In this Motley Fool Live video recorded on July 7, Motley Fool contributors Keith Speights and Brian Orelli discuss Lilly's latest results.
Source Fool.com